

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
COMPLETION OF PHASE Ib CLINICAL TRIALS OF
PYRILUTAMIDE (KX-826) IN THE UNITED STATES**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”).

On 3 August 2020, the Group completed the phase Ib clinical trials of Ppyrilutamide (KX-826) in the United States. Ppyrilutamide (KX-826) is a potential first-in-class small molecule AR antagonist the Group is developing for the treatment of androgenetic alopecia, with ongoing clinical trials in both China and the United States.

The phase Ib clinical trials of Ppyrilutamide (KX-826) in the United States is a randomised, double-blind, placebo-controlled, parallel group, dose escalation study in healthy male subjects with androgenetic alopecia to evaluate the safety, tolerability and pharmacokinetics of Ppyrilutamide (KX-826) following topical multiple ascending dose administration. A total of 40 healthy male subjects with androgenetic alopecia were enrolled to be evaluated with 32 subjects randomised to receive active drug and eight subjects randomised to receive placebo in a double-blind manner (10 subjects in each dose cohort with two subjects randomised to placebo) for a total of four dose cohorts. Dose levels of 2.5 mg, 5 mg, 10 mg and 20 mg of Ppyrilutamide (KX-826) as a topical application are being evaluated.

The execution of these phase Ib clinical trials was smooth and steady, and was not materially affected by the current COVID-19 pandemic situation in the United States. The Group is analysing and evaluating the data collected in the phase Ib clinical trials of Ppyrilutamide (KX-826) in the United States and expects to finalise the clinical study report (CSR) and release the data in the fourth quarter of 2020.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Executive Director

Hong Kong, 4 August 2020

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Dr. Chuangxing Guo, Mr. Gang Lu, Mr. Jie Chen, Dr. Bing Chen and Mr. Wei Zhang; and the independent non-executive Directors are Dr. Michael Min Xu, Dr. John Fenyu Jin and Mr. Wallace Wai Yim Yeung.

* *For identification purpose only*